CliniMACS® CD14 Product Line

CliniMACS
®
CD14 Product Line

The CD14 antigen is a high-affinity receptor for the lipopolysaccharide (LPS) and LPS-binding protein (LPB) complex.
CD14 is strongly expressed on most human monocytes and macrophages.
The CliniMACS® CD14 Product Line consists of murine anti-CD14 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD14 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.

Disclaimer

The CliniMACS
®
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for
in vitro
use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS GMP MicroBeads are for research use and
ex vivo
cell processing only.
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.

Applications

The CliniMACS CD14 Product Line was developed for the enrichment of CD14
+
cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.
The enriched cells can be used for the subsequent generation of human monocyte-derived dendritic cells (MoDCs).
1

Referenced literature

DCs generated from monocytes after the enrichment of CD14
+
cells are well characterized and have been used for active vaccination in many clinical trials, mainly in solid tumors and hematological malignancies.
2-8
Based on new insight into cellular interactions, an interesting therapeutic option might be the administration of MoDCs in combination with the modification of other cell populations, for example, depletion of regulatory T cells. Furthermore, the targeted manipulation of MoDCs, for example, by electroporation with mRNA, might be a very promising and innovative approach to improve the efficacy of DCs.
8
  • Selected references

    1. Campbell, J. D. et al. (2005) Isolation and generation of clinical-grade dendritic cells using the CliniMACS system. Methods Mol. Med. 109: 55-69
    2. Curti et al. (2007) Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol. 139: 415-424
    3. Babatz et al. (2006) Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother. 55: 268-76
    4. Mazzolini, G. et al. (2005) Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol. 10: 999-1010
    5. Di Nicola et al. (2009) Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113(1): 18-27
    6. Sorg, R. V. et al. (2003) Clinical-scale generation of dendritic cells in a closed system. J. Immunother. 26: 374-383
    7. Schwaab et al. (2009) Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15: 4986-4992
    8. Van Tendeloo, V. F. et al. (2010) Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. U.S.A. 107(31): 13824-13829
  • Selected references

  • Scientific posters

  • Certificates

    Please follow this
    link
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 3
1
kit
-
200-070-118

CliniMACS CD14 Reagent (272-01)

7.5 mL
CHF  3'690.00
1
kit
CHF  5'160.00